A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

BIO-Europe Startup Spotlight returns to Lisbon in March 2026, showcasing Europe’s top early-stage biotech pitches to industry ...

Ghent is boosting its biopharma hub with cutting-edge infrastructure, world-class research, and a thriving life sciences ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.

The companies Cogent Biosciences, Braveheart Bio, and AAVantgarde bagged the biggest biotech funding rounds overall in November 2025.

AstraZeneca was involved in one of the standout I&I deals of 2025 as it entered into a global strategic collaboration with Harbour BioMed in March that involved an upfront payment, near-term milestone ...

In one of the standout deals of the year so far, Roche entered into a $5.3 billion collaboration and license agreement with peptide therapeutics company Zealand Pharma to co-develop and ...

The mechanism of GLP-1 agonists is straightforward. They mimic the effects of the naturally occurring hormone, GLP-1, which regulates blood sugar and appetite in the body. While they are highly ...